APA (7th ed.) Citation

Madsen, B. S., Trebicka, J., Thiele, M., Israelsen, M., Arumugan, M., Havelund, T., & Krag, A. (2018). Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease: Study protocol for a randomized controlled trial. BMC.

Chicago Style (17th ed.) Citation

Madsen, Bjørn Stæhr, Jonel Trebicka, Maja Thiele, Mads Israelsen, Manimozhiyan Arumugan, Troels Havelund, and Aleksander Krag. Antifibrotic and Molecular Aspects of Rifaximin in Alcoholic Liver Disease: Study Protocol for a Randomized Controlled Trial. BMC, 2018.

MLA (9th ed.) Citation

Madsen, Bjørn Stæhr, et al. Antifibrotic and Molecular Aspects of Rifaximin in Alcoholic Liver Disease: Study Protocol for a Randomized Controlled Trial. BMC, 2018.